Hemorrhagic profile of the fibrinolytic alfimeprase after ischemia and reperfusion
- 1 March 2009
- journal article
- Published by Taylor & Francis in Neurological Research
- Vol. 31 (2) , 209-214
Abstract
Recanalization therapies for ischemic stroke have been slow to change clinical practice because of perceived and published risks of hemorrhage associated with lytic administration. We quantified alfimeprase in an acute ischemia-reperfusion model, as compared with recombinant tissue plasminogen activator, with hemorrhagic transformation as the primary endpoint and infarction volume and blood-brain barrier permeability as secondary endpoints. Five groups were studied in a blinded fashion: alfimeprase at doses of 0.03 (n=8), 0.1 (n=11) and 0.3 mg/kg (n=8); recombinant tissue plasminogen activator at 1 mg/kg (n=9); carrier infused controls (n=9). The middle cerebral artery was occluded for 5 hours followed by removal of the suture for reperfusion. Drugs were infused immediately following reperfusion over a 10-minute period. Approximately 24 hours later, the animals were anesthetized and decapitated, and the brains were rapidly harvested and frozen. Serial brain sections were obtained and inspected for hemorrhages. Infarction and blood-brain barrier permeability were also evaluated in additional experiments in control, 0.1 mg/kg alfimeprase and 1 mg/kg recombinant tissue plasminogen activator-treated rats. The hemorrhagic transformation frequency, neurological deficit and the mortality rate of alfimeprase were significantly lower than for recombinant tissue plasminogen activator at the 0.03 mg/kg dose and not statistically different at the higher doses. Infarction and blood-brain barrier permeability were not significantly different among control, 0.1 mg/kg alfimeprase and recombinant tissue plasminogen activator. In this model, alfimeprase, a new fibrinolytic agent, exhibits a profile comparable to recombinant tissue plasminogen activator.Keywords
This publication has 13 references indexed in Scilit:
- Letter by Brilakis and Banerjee Regarding Article, “Impact of Internal Mammary Artery Conduit on Long-Term Outcomes After Percutaneous Intervention of Saphenous Vein Graft”Circulation, 2006
- Phase II Trial of Alfimeprase, a Novel-Acting Fibrin Degradation Agent, for Occluded Central Venous Access DevicesJournal of Clinical Oncology, 2006
- Mild hypothermia enhances the neuroprotective effects of FK506 and expands its therapeutic window following transient focal ischemia in ratsBrain Research, 2004
- Ischaemic brain oedemaJournal of Clinical Neuroscience, 2002
- Optimal Depth and Duration of Mild Hypothermia in a Focal Model of Transient Cerebral IschemiaStroke, 1998
- A rat model of focal embolic cerebral ischemiaBrain Research, 1997
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Mild Intraischemic Hypothermia Reduces Postischemic Hyperperfusion, Delayed Postischemic Hypoperfusion, Blood-Brain Barrier Disruption, Brain Edema, and Neuronal Damage Volume after Temporary Focal Cerebral Ischemia in RatsJournal of Cerebral Blood Flow & Metabolism, 1994
- Fibrinolytic enzymes from the venoms of Agkistrodon contortrix contortrix and Crotalus basiliscus basiliscus: Cleavage site specificity towards the α-chain of fibrinThrombosis Research, 1994
- A direct-acting fibrinolytic enzyme from the venom of Agkistrodon contortrix contortrix: Effects on various components of the human blood coagulation and fibrinolysis systemsThrombosis Research, 1988